Milestone Pharmaceuticals
MIST
34 hedge funds and large institutions have $138M invested in Milestone Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 14 increasing their positions, 7 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 7
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
24% more capital invested
Capital invested by funds: $111M → $138M (+$26.7M)
10% more funds holding
Funds holding: 31 → 34 (+3)
6.32% more ownership
Funds ownership: 62.66% → 68.99% (+6.3%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$14.1M |
| 2 |
SCM
Suvretta Capital Management
New York
|
+$5.7M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
+$4.69M |
| 4 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$3.01M |
| 5 |
Millennium Management
New York
|
+$2.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$2.31M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.35M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$610K |
| 4 |
CAC
Cowen and Company
New York
|
-$88K |
| 5 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$45.9K |
MIST Hedge Fund Activity: Q4 2020 in Review
34 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Milestone Pharmaceuticals (MIST) for Q4 2020, worth a combined $138M — up 24% from $111M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new MIST positions and 5 closed out — a net gain of 3 holders — while 14 added to existing stakes and 7 trimmed.
The largest buyer was OrbiMed, adding an estimated $14.1M. The largest seller was Invesco, exiting entirely with an estimated $2.31M sold.
- 34 institutional investors held Milestone Pharmaceuticals (MIST) as of Q4 2020, up from 31 in Q3 2020.
- Funds reported $138M of Milestone Pharmaceuticals stock for Q4 2020, up 24% quarter-over-quarter.
- 8 funds opened new Milestone Pharmaceuticals positions in Q4 2020 and 5 closed out, a net change of +3 holders.
- The largest Milestone Pharmaceuticals buyer in Q4 2020 was OrbiMed, an estimated $14.1M added.
- The largest Milestone Pharmaceuticals seller in Q4 2020 was Invesco, an estimated $2.31M sold.
Based on aggregated 13F filings for Q4 2020.